2024 HCPCS Code G8969
Documentation of patient reason(s) for not prescribing an oral anticoagulant that is fda approved for the prevention of thromboembolism (e.g., patient preference for not receiving anticoagulation)
TAGS: anticoagulant prescribing preference documentation patient approved thromboembolism receiving prevention
| Short Description | Doc pt rsn no presc warf/fda |
| HCPCS Coverage Code | C - Carrier judgment |
| HCPCS Action Code | N - No maintenance for this code |
| HCPCS Action Effective Date | January 01, 2022 |
| HCPCS Code Added Date | January 01, 2013 |
| HCPCS Pricing Indicator Code | 00 - Service not separately priced by part B (e.G., services not covered, bundled, used by part a only, etc.) |
| HCPCS Multiple Pricing Indicator Code | 9 - Not applicable as HCPCS not priced separately by part B (pricing indicator is 00) or value is not established (pricing indicator is '99') |
| HCPCS Coverage Issues Manual Reference Section Number | |
| HCPCS Type Of Service Code | 1 - Medical care |
| HCPCS Anesthesia Base Unit Quantity | 0 |
Check Similar HCPCS Codes
- G9008 - Mccd,phys coor-care ovrsght
- G9009 - Mccd, risk adj, level 3
- G9010 - Mccd, risk adj, level 4
- G9011 - Mccd, risk adj, level 5
- G9012 - Other specified case mgmt
- G9013 - Esrd demo bundle level i
- G9014 - Esrd demo bundle-level ii
- G9016 - Demo-smoking cessation coun
- G9017 - Amantadine hcl 100mg oral
- G9018 - Zanamivir,inhalation pwd 10m
- G9019 - Oseltamivir phosphate 75mg
- G9020 - Rimantadine hcl 100mg oral
- G9033 - Amantadine hcl oral brand
- G9034 - Zanamivir, inh pwdr, brand
- G9035 - Oseltamivir phosp, brand
- G9036 - Rimantadine hcl, brand
- G9037 - Intrpro req fr rec phys/qhcp
- G9038 - Co-management services
- G9050 - Oncology work-up evaluation
- G9051 - Oncology tx decision-mgmt